

RPG LIFE SCIENCES LIMITED Unit No. 208-213, B Wing, Bezzola Complex, Sion-Trombay Road, Chembur, Mumbai 400071, India Tel: +91-22-25292152-55 Fax: +91-22-25297423

January 31, 2020

To,

The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor Plot No. C1, 'G' Block, Bandra-Kurla Complex Bandra (East), Mumbai 400 051. BSE Limited Corporate Relationship Department Floor 25, P.J. Towers Dalal Street Mumbai 400 001.

Symbol: RPGLIFE

Scrip code: 532983

Dear Sirs,

Sub: Press Release - Financial Results

Please find enclosed herewith a copy of press release with respect to Unaudited Financial Results of the Company for the quarter ended December 31, 2019.

Kindly take the above on record.

Thanking you,

Yours faithfully, For RPG Life Sciences Limited

Rajesh Shirambekar

Head – Legal & Company Secretary

Encl: as above





RPG Life Sciences Q3 Profit Before Tax grows by 43.6%

Mumbai, 31 January, 2020: RPG Life Sciences Limited has announced its financial results for the quarter ended December 31st, 2019.

	YoY Net Revenue from Operations	YoY PBT from Operations
Q3 FY 20 Highlights	Rs 94.37 crores-up from Rs 90.97 crores	Rs 10.41 crores-up from Rs 7.25 crores
Nine Months FY 20 Highlights	Rs 286.90 crores-up from Rs 261.36 crores	Rs 33.31 crores-up from Rs 12.93 crores

RPG Life Sciences, engaged in the manufacturing and marketing of pharmaceutical products, posted its Q3 and Nine months results. Q3 revenue is higher than the corresponding quarter last year and PBT has registered a significant jump from Rs 7.25 crores to Rs 10.41 crores. Overall, during nine months, Company's PBT stood at Rs 33.31 crores versus Rs 12.93 crores over similar period last year and revenue increased by 10%.

"Q3 results are consistent with those of Q1 and Q2 both on revenue and profit fronts. The turn-around performance is largely driven by the biggest contributing Domestic business, which grew over 23%. Focus has been on prescription generation, product portfolio rejuvenation, sales force effectiveness enhancement with strict vigil on Sales hygiene." said Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd.

	 EDITDA margins improved from 13.3% to 15.8% 	
Q3 FY20 Other Highlights (y-o-y)	Domestic formulations sales grew over 23% with all majo registering healthy growth	r <mark>brands</mark>
	3. Global ROW Sales grew by 26%	
Nine months FY20 Other	1. EDITDA margins improved from 10.5% to 16.4%	
Nine months FY20 Other Highlights (y-o-y)	 EDITDA margins improved from 10.5% to 16.4% Domestic formulations sales grew over 23.4% with all major registering healthy double-digit growth 	r brands

RPG Life Sciences Ltd (www.rpglifesciences.com):

RPG Life Sciences Ltd, part of RPG Enterprises, is an integrated pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The Company is a research-based pharmaceutical Company, producing a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients.

RPG Enterprises (www.rpggroup.com):

RPG Enterprises, established in 1979, is one of India's fastest growing business groups with a turnover of US\$ 4 Billion. The group has diverse business interests in the areas of Infrastructure, Tyres, Pharma, IT and Specialty as well as in emerging innovation-led technology businesses.

Media Contact: Sumeet Chatterjee Senior Vice President – Group Communications <u>sumeet@rpg.in</u> +91 9820340650

